On the relative safety of parenteral iron formulations
- PMID: 15150356
- DOI: 10.1093/ndt/gfh185
On the relative safety of parenteral iron formulations
Abstract
Background: Intravenous iron is usually required to optimize the correction of anaemia in persons with advanced chronic kidney disease and end-stage renal disease. Randomized clinical trials may have insufficient power to detect differences in the safety profiles of specific formulations.
Methods: We obtained data from the US Food and Drug Administration on reported adverse drug events (ADEs) related to the provision of three formulations of intravenous iron during 1998-2000. We estimated the relative risks [odds ratios (OR)] of ADEs associated with the use of higher molecular weight iron dextran and sodium ferric gluconate complex compared with lower molecular weight iron dextran using 2 x 2 tables.
Results: The total number of reported parenteral iron-related ADEs was 1981 among approximately 21,060,000 doses administered, yielding a rate of 9.4 x 10(-5), or approximately 94 per million. Total major ADEs were significantly increased among recipients of higher molecular weight iron dextran (OR 5.5, 95% CI 4.9-6.0) and sodium ferric gluconate complex (OR 6.2, 95% CI 5.4-7.2) compared with recipients of lower molecular weight iron dextran. We observed significantly higher rates of life-threatening ADEs, including death, anaphylactoid reaction, cardiac arrest and respiratory depression among users of higher molecular weight compared with lower molecular weight iron dextran. There was insufficient power to detect differences in life-threatening ADEs when comparing lower molecular weight iron dextran with sodium ferric gluconate complex.
Conclusions: Parenteral iron-related ADEs are rare. Using observational data, overall and most specific ADE rates were significantly higher among recipients of higher molecular weight iron dextran and sodium ferric gluconate complex than among recipients of lower molecular weight iron dextran. These data may help to guide clinical practice, as head-to-head clinical trials comparing different formulations of intravenous iron have not been conducted.
Comment in
-
Do we need to change our administration practice with regard to sodium ferric gluconate complex in glucose?Nephrol Dial Transplant. 2005 Jun;20(6):1279. doi: 10.1093/ndt/gfh552. Epub 2005 Mar 29. Nephrol Dial Transplant. 2005. PMID: 15797892 No abstract available.
Similar articles
-
Update on adverse drug events associated with parenteral iron.Nephrol Dial Transplant. 2006 Feb;21(2):378-82. doi: 10.1093/ndt/gfi253. Epub 2005 Nov 11. Nephrol Dial Transplant. 2006. PMID: 16286429
-
Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.Am J Kidney Dis. 1999 Mar;33(3):464-70. doi: 10.1016/s0272-6386(99)70183-6. Am J Kidney Dis. 1999. PMID: 10070910 Review.
-
The comparative safety of various intravenous iron preparations in chronic kidney disease patients.Ren Fail. 2008;30(6):629-38. doi: 10.1080/08860220802134631. Ren Fail. 2008. PMID: 18661414 Clinical Trial.
-
Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.Kidney Int. 2002 May;61(5):1830-9. doi: 10.1046/j.1523-1755.2002.00314.x. Kidney Int. 2002. PMID: 11967034 Clinical Trial.
-
Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.Kidney Int. 2008 Mar;73(5):528-30. doi: 10.1038/sj.ki.5002779. Kidney Int. 2008. PMID: 18274543 Review.
Cited by
-
Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?Eur J Hosp Pharm. 2018 Mar;25(2):79-84. doi: 10.1136/ejhpharm-2016-001059. Epub 2017 Jan 23. Eur J Hosp Pharm. 2018. PMID: 29599970 Free PMC article.
-
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.Drug Saf. 2022 Oct;45(10):1019-1036. doi: 10.1007/s40264-022-01216-w. Epub 2022 Sep 6. Drug Saf. 2022. PMID: 36068430 Free PMC article.
-
Safety issues with intravenous iron products in the management of anemia in chronic kidney disease.Clin Med Res. 2008 Dec;6(3-4):93-102. doi: 10.3121/cmr.2008.811. Clin Med Res. 2008. PMID: 19325171 Free PMC article. Review.
-
Safety of intravenous iron use in chronic kidney disease.Curr Opin Nephrol Hypertens. 2016 Nov;25(6):529-535. doi: 10.1097/MNH.0000000000000263. Curr Opin Nephrol Hypertens. 2016. PMID: 27557350 Free PMC article. Review.
-
Data mining of the public version of the FDA Adverse Event Reporting System.Int J Med Sci. 2013 Apr 25;10(7):796-803. doi: 10.7150/ijms.6048. Print 2013. Int J Med Sci. 2013. PMID: 23794943 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical